Elicio Therapeutics (ELTX) Retained Earnings (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Retained Earnings for 7 consecutive years, with $261.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 20.18% year-over-year to $261.7 million; the trailing twelve-month figure through Jun 2026 stood at $261.7 million (up 20.18% YoY), and the FY2025 full-year result was $235.4 million, up 221.28% from the prior year.
• Retained Earnings grew to $261.7 million in Q2 2026 per ELTX's latest filing, from -$245.5 million in the prior quarter.
• Across five years, Retained Earnings topped out at $297.9 million in Q2 2022 and bottomed at -$245.5 million in Q1 2026.
• Historically, Retained Earnings has averaged $114.8 million across 5 years, with a median of $186.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings jumped 243.75% in 2023, then slumped 226.18% in 2024.
• Over 5 years, Retained Earnings stood at -$107.0 million in 2022, then surged by 243.75% to $153.8 million in 2023, then plunged by 226.18% to -$194.1 million in 2024, then jumped by 221.28% to $235.4 million in 2025, then gained by 11.17% to $261.7 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $261.7 million, -$245.5 million, and $235.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.